I understand CXS doing early due diligence on CYT as CXS exhibits greater conficence of upcoming successful IND approval in US for omacetaxine. Clearly CXS looking to access additional local well advanced oncology drug development programs and exhibiting confidence its own management to repeat what others have struggled to do themselves in this country. Will be watching closely.
acquisition
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
